Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary

Postgrad Med. 2009 Mar;121(2):202-4. doi: 10.3810/pgm.2009.03.1995.
No abstract available

Publication types

  • Comment